The data suggest that using these markers, the Aβ(1-42)/P-tau ratio gives the most robust indicator of a patient transitioning from MCI to AD, and the follow-up period for longitudinal evaluations is identified as especially critical to clinical study design for this purpose. This evidence concerns the gene MAPT and Alzheimer disease.